Allogeneic bone marrow transplantation restores IGF-I production and linear growth in a gamma-SCID patient with abnormal growth hormone receptor signaling

Bone Marrow Transplant. 2004 Apr;33(7):773-5. doi: 10.1038/sj.bmt.1704421.

Abstract

Severe combined immunodeficiency (SCID) is a heterogeneous group of disorders characterized by a severe defect of both T- and B-cell immunity, which generally require allogeneic bone marrow transplantation (BMT) within the first years of life. We previously reported a patient affected with an X-linked SCID due to L183S hemizygous missense gamma chain mutation, whose severe short stature was due to a peripheral growth hormone (GH) hyporesponsiveness associated to abnormal GH receptor (GH-R) signal transduction. In this study, we report the effect of BMT on the GH-R/insulin-like growth factor I (IGF-I) axis. After BMT, the patient showed a significant improvement in linear growth and normalization of basal- and GH-stimulated IGF-I values, which paralleled a fully competent immunological reconstitution. This suggests that cells derived from the hematopoietic stem cell may exert an unexpectedly significant role in producing IGF-I. This may also suggest that stem cell-based therapies may be useful for the correction of non-hematopoietic inherited disorders, such as those of GH-R/IGF-I axis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow Transplantation*
  • Graft Survival
  • Growth*
  • Humans
  • Immune System / physiology
  • Immunoglobulin gamma-Chains / genetics
  • Infant
  • Insulin-Like Growth Factor I / biosynthesis*
  • Insulin-Like Growth Factor I / deficiency
  • Male
  • Receptors, Somatotropin
  • Regeneration
  • Severe Combined Immunodeficiency / therapy*
  • Signal Transduction
  • Transplantation, Homologous

Substances

  • Immunoglobulin gamma-Chains
  • Receptors, Somatotropin
  • Insulin-Like Growth Factor I